the Detection of Prostate Cancer in MenNCT07075666
Early Detection of Prostate Cancer of Syrian Men
An observational study of the Detection of Prostate Cancer in Men, run by Al-Hawash Private University at 1 site in Syria.
Trial summary
Prostate cancer is a significant health concern in the Middle East, including Syria, where many cases are diagnosed at advanced stages due to low awareness and inadequate screening practices. Read more about this study
- Who is it for?
- Ages 40 to 65 years, men only
- Conditions the study is for
- the Detection of Prostate Cancer in Men
- What is being tested?
- PSA and DRE
- How many people
- 1,000 participants
- Where
- 1 siteSyria
- Study dates
- 17 May 2025to 30 Jul 2025
- How long will I take part?
- 6 Months
- Phase
- Observational
- Are there results?
- Not yet: the study is under way
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 40 to 65 years
- Men only
- Adult, Older adult
Study population: Detection of Prostate cancer in syrian men aged 40-65
Who may be able to join
- Men aged 40 years and older residing in the middle region of Syria.
Who cannot join
- Men with a previous diagnosis of prostate cancer.
Trial locations and contacts
1 site in 1 country. Contact the study team or a site near you to ask about taking part.
About this study
Official title: Early Detection of Prostate Cancer Among Men in the Middle Region of Syria
Prostate cancer is a significant health concern in the Middle East, including Syria, where many cases are diagnosed at advanced stages due to low awareness and inadequate screening practices. The mortality-to-incidence ratio for prostate cancer in the region is alarmingly high, indicating a pressing need for effective early detection strategies.
Read the detailed description
This study aims to assess the awareness, attitudes, and practices regarding prostate cancer screening among men in the middle region of Syria, with the goal of identifying barriers to early detection and informing public health interventions.
- Conditions
- the Detection of Prostate Cancer in Men
- Being tested
- PSA, DRE
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
PSADiagnostic test
Prostate-Specific Antigen test, a blood test used to measure the level of PSA in a man's blood. PSA is a protein produced by the prostate gland, and elevated levels can indicate various conditions, including prostate cancer, benign prostatic hyperplasia (BPH), or prostatitis.
DREDiagnostic test
A digital rectal exam (DRE) is a procedure where a doctor inserts a lubricated, gloved finger into the rectum to check for abnormalities.
What is being measured
The primary outcome is the main question the study is designed to answer.
Number of ptients with early signs of prostate cancer
Measured: From Participant enrolment to the end of the study at 2 weeks
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted20 Jul 2025
- Study start17 May 2025
- Primary completion31 May 2025
- Study completion30 Jul 2025 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for the Detection of Prostate Cancer in MenStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Observational
- Observational model
- Cohort
- Time perspective
- Cross-sectional
- Enrolment
- 1,000 participants (estimated)
- Target duration
- 6 Months
Sponsor and investigators
- Lead sponsor
- Al-Hawash Private University
- Sponsor type
- University, hospital or other
- Responsible party
- Sponsor
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT07075666
- Sponsor's protocol ID
- 02-05-2025
- Status last verified
- Jul 2025
- First submitted
- 11 Jul 2025
- Last updated
- 20 Jul 2025
- Results posted
- No
- Data monitoring committee
- Yes
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- No
Study at a glance
From the registry record, last updated by the sponsor on 20 Jul 2025. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Early Detection of Prostate Cancer Among Men in the Middle Region of Syria
- ClinicalTrials.gov ID
- NCT07075666
- Acronym / sponsor ID
- 02-05-2025
- Conditions
- the Detection of Prostate Cancer in Men
- Study type
- Observational
- Recruitment status
- Enrolling by invitation
- Enrolment
- 1,000 participants (estimated)
- Lead sponsor
- Al-Hawash Private UniversityUniversity, hospital or other
- Study start
- 17 May 2025 (actual)
- Primary completion
- 31 May 2025 (actual)
- Study completion
- 30 Jul 2025 (estimated)
- First posted
- 20 Jul 2025 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
Prostate cancer is a significant health concern in the Middle East, including Syria, where many cases are diagnosed at advanced stages due to low awareness and inadequate screening practices. The mortality-to-incidence ratio for prostate cancer in the region is alarmingly high, indicating a pressing need for effective early detection strategies.
Detailed description
This study aims to assess the awareness, attitudes, and practices regarding prostate cancer screening among men in the middle region of Syria, with the goal of identifying barriers to early detection and informing public health interventions.
Study design
- Observational model
- Cohort
- Time perspective
- Cross-sectional
- Target follow-up
- 6 Months
Who may qualify
- Ages
- 40 to 65 years
- Sex
- Male only
- Age groups
- Adult, Older adult
- Study population
- Detection of Prostate cancer in syrian men aged 40-65
Key inclusion criteria (1 listed)
- Men aged 40 years and older residing in the middle region of Syria.
Key exclusion criteria (1 listed)
- Men with a previous diagnosis of prostate cancer.
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| PSAProstate-Specific Antigen test, a blood test used to measure the level of PSA in a man's blood. PSA is a protein produced by the prostate gland, and elevated levels can indicate various conditions, including prostate cancer, benign prostatic hyperplasia (BPH), or prostatitis. | Diagnostic test | – |
| DREA digital rectal exam (DRE) is a procedure where a doctor inserts a lubricated, gloved finger into the rectum to check for abnormalities. | Diagnostic test | – |
Primary outcome
Number of ptients with early signs of prostate cancer
Time frame: From Participant enrolment to the end of the study at 2 weeks
Results and safety
This study is still under way. Results are not available in the source record yet.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 20 Jul 2025.
- Individual participant dataSharing planned: No
Related trials for the Detection of Prostate Cancer in Men
Recruiting
Comparing PSMA PET/CT and MRI-RSI for Finding and Outlining Tumors Inside the Prostate in Men With Newly Diagnosed Prostate Cancer
Prostate Cancer
Active, not recruitingPhase 2
Study of PSMA-targeted 18F-DCFPyL PET/CT for the Detection of Clinically Significant Prostate Cancer
Prostate Cancer
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part.
The record lists no contact. Use the official record to reach the sponsor.
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
An observational study of the Detection of Prostate Cancer in Men, run by Al-Hawash Private University at 1 site in Syria.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 1 inclusion and 1 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: enrolling by invitation, as of the sponsor's last update on 20 Jul 2025. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in Syria. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
This study is still under way. Results are not available in the source record yet.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Number of ptients with early signs of prostate cancer (time frame: From Participant enrolment to the end of the study at 2 weeks). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 20 Jul 2025.